Cargando…

1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022

BACKGROUND: Tick-borne encephalitis (TBE) is an infection by the tickborne encephalitis virus that causes symptoms of central nervous system inflammation (meningitis, encephalitis, etc.). TBE is endemic in parts of Europe including the Czech Republic. In 2020, 23% of 3,734 TBE cases reported to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyncl, Jan, Angulo, Frederick, Orlikova, Hana, Zhang, Pingping, Vlckova, Iva, Maly, Marek, Krivohlavkova, Dagmar, Harper, Lisa, Edwards, Juanita, Bender, Cody, Pilz, Andreas, Erber, Wilhelm, Madhava, Harish, Moïsi, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679031/
http://dx.doi.org/10.1093/ofid/ofad500.1588
_version_ 1785150497667153920
author Kyncl, Jan
Angulo, Frederick
Orlikova, Hana
Zhang, Pingping
Vlckova, Iva
Maly, Marek
Krivohlavkova, Dagmar
Harper, Lisa
Edwards, Juanita
Bender, Cody
Pilz, Andreas
Erber, Wilhelm
Madhava, Harish
Moïsi, Jennifer
author_facet Kyncl, Jan
Angulo, Frederick
Orlikova, Hana
Zhang, Pingping
Vlckova, Iva
Maly, Marek
Krivohlavkova, Dagmar
Harper, Lisa
Edwards, Juanita
Bender, Cody
Pilz, Andreas
Erber, Wilhelm
Madhava, Harish
Moïsi, Jennifer
author_sort Kyncl, Jan
collection PubMed
description BACKGROUND: Tick-borne encephalitis (TBE) is an infection by the tickborne encephalitis virus that causes symptoms of central nervous system inflammation (meningitis, encephalitis, etc.). TBE is endemic in parts of Europe including the Czech Republic. In 2020, 23% of 3,734 TBE cases reported to the European Centre for Disease Prevention and Control were from the Czech Republic. TBE vaccination is universally recommended in the Czech Republic, but TBE vaccine effectiveness (VE) has not been assessed. METHODS: Laboratory-confirmed TBE is a notifiable disease in the Czech Republic with mandatory reporting by clinicians to public health authorities. Vaccine histories of TBE cases were determined by medical record review and interviews. Online household surveys on vaccine uptake were conducted in 2019-2020. A person who received the three-dose primary series and who was not late for the subsequent booster(s) was fully-vaccinated. VE against TBE was determined by comparing the proportion of TBE cases who were fully-vaccinated (PCV) and the proportion of survey respondents who were fully-vaccinated (PPV), excluding partially-vaccinated, using the screening method formula VE=1-[PCV/(1-PCV)]/[PPV/(1-PPV)]. RESULTS: In 2018-2022, 3648 TBE cases were reported in the Czech Republic; 98.1% (3105/3166) of TBE cases with known vaccination history were unvaccinated. The incidence of TBE was 6.8/100,000 population per year (PPY); the highest incidence was in the southwestern Jihočeský region (17.8/100,000 PPY). Of the TBE cases with known hospitalization, 94.5% (3324/3517) were hospitalized. There were 20 (0.55%) deaths. Among 42,671 persons surveyed with known TBE vaccination history, 66.5% were unvaccinated. VE for the prevention of TBE was 97.6% (95% confidence interval 95.7-98.7). By age groups, VE was 97.1% (88.4-99.3) in 1-15 years-of-age, 97.9% (95.3-99.0) in 16-59 years-of-age, and 96.9% (90.5-99.0) in > 60 years-of-age. TBE vaccination averted an estimated 1020 TBE cases in the Czech Republic from 2018-2022. CONCLUSION: TBE vaccination was highly effective in preventing TBE in the Czech Republic. The protective effect of TBE vaccines was evident in all age groups. To prevent additional TBE cases in the Czech Republic and elsewhere, efforts to increase TBE vaccine uptake are needed. DISCLOSURES: Frederick Angulo, DVM PhD, Pfizer Vaccines: Employee|Pfizer Vaccines: Stocks/Bonds Pingping Zhang, MS, Pfizer Vaccines: Stocks/Bonds Dagmar Krivohlavkova, M.D., Pfizer Vaccine: Employee|Pfizer Vaccine: Stocks/Bonds Lisa Harper, M.S., Pfizer Vaccines: Stocks/Bonds Juanita Edwards, B.S., Pfizer Vaccines: Stocks/Bonds Cody Bender, M.S., Pfizer Vaccines: Stocks/Bonds Andreas Pilz, PhD, Pfizer Vaccines: Stocks/Bonds Wilhelm Erber, PhD, Pfizer Vaccines: Stocks/Bonds Harish Madhava, M.D., Pfizer Vaccines: Stocks/Bonds Jennifer Moïsi, PhD, Pfizer Vaccines: Stocks/Bonds
format Online
Article
Text
id pubmed-10679031
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106790312023-11-27 1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022 Kyncl, Jan Angulo, Frederick Orlikova, Hana Zhang, Pingping Vlckova, Iva Maly, Marek Krivohlavkova, Dagmar Harper, Lisa Edwards, Juanita Bender, Cody Pilz, Andreas Erber, Wilhelm Madhava, Harish Moïsi, Jennifer Open Forum Infect Dis Abstract BACKGROUND: Tick-borne encephalitis (TBE) is an infection by the tickborne encephalitis virus that causes symptoms of central nervous system inflammation (meningitis, encephalitis, etc.). TBE is endemic in parts of Europe including the Czech Republic. In 2020, 23% of 3,734 TBE cases reported to the European Centre for Disease Prevention and Control were from the Czech Republic. TBE vaccination is universally recommended in the Czech Republic, but TBE vaccine effectiveness (VE) has not been assessed. METHODS: Laboratory-confirmed TBE is a notifiable disease in the Czech Republic with mandatory reporting by clinicians to public health authorities. Vaccine histories of TBE cases were determined by medical record review and interviews. Online household surveys on vaccine uptake were conducted in 2019-2020. A person who received the three-dose primary series and who was not late for the subsequent booster(s) was fully-vaccinated. VE against TBE was determined by comparing the proportion of TBE cases who were fully-vaccinated (PCV) and the proportion of survey respondents who were fully-vaccinated (PPV), excluding partially-vaccinated, using the screening method formula VE=1-[PCV/(1-PCV)]/[PPV/(1-PPV)]. RESULTS: In 2018-2022, 3648 TBE cases were reported in the Czech Republic; 98.1% (3105/3166) of TBE cases with known vaccination history were unvaccinated. The incidence of TBE was 6.8/100,000 population per year (PPY); the highest incidence was in the southwestern Jihočeský region (17.8/100,000 PPY). Of the TBE cases with known hospitalization, 94.5% (3324/3517) were hospitalized. There were 20 (0.55%) deaths. Among 42,671 persons surveyed with known TBE vaccination history, 66.5% were unvaccinated. VE for the prevention of TBE was 97.6% (95% confidence interval 95.7-98.7). By age groups, VE was 97.1% (88.4-99.3) in 1-15 years-of-age, 97.9% (95.3-99.0) in 16-59 years-of-age, and 96.9% (90.5-99.0) in > 60 years-of-age. TBE vaccination averted an estimated 1020 TBE cases in the Czech Republic from 2018-2022. CONCLUSION: TBE vaccination was highly effective in preventing TBE in the Czech Republic. The protective effect of TBE vaccines was evident in all age groups. To prevent additional TBE cases in the Czech Republic and elsewhere, efforts to increase TBE vaccine uptake are needed. DISCLOSURES: Frederick Angulo, DVM PhD, Pfizer Vaccines: Employee|Pfizer Vaccines: Stocks/Bonds Pingping Zhang, MS, Pfizer Vaccines: Stocks/Bonds Dagmar Krivohlavkova, M.D., Pfizer Vaccine: Employee|Pfizer Vaccine: Stocks/Bonds Lisa Harper, M.S., Pfizer Vaccines: Stocks/Bonds Juanita Edwards, B.S., Pfizer Vaccines: Stocks/Bonds Cody Bender, M.S., Pfizer Vaccines: Stocks/Bonds Andreas Pilz, PhD, Pfizer Vaccines: Stocks/Bonds Wilhelm Erber, PhD, Pfizer Vaccines: Stocks/Bonds Harish Madhava, M.D., Pfizer Vaccines: Stocks/Bonds Jennifer Moïsi, PhD, Pfizer Vaccines: Stocks/Bonds Oxford University Press 2023-11-27 /pmc/articles/PMC10679031/ http://dx.doi.org/10.1093/ofid/ofad500.1588 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Kyncl, Jan
Angulo, Frederick
Orlikova, Hana
Zhang, Pingping
Vlckova, Iva
Maly, Marek
Krivohlavkova, Dagmar
Harper, Lisa
Edwards, Juanita
Bender, Cody
Pilz, Andreas
Erber, Wilhelm
Madhava, Harish
Moïsi, Jennifer
1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022
title 1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022
title_full 1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022
title_fullStr 1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022
title_full_unstemmed 1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022
title_short 1757. Effectiveness of vaccination against tick-borne encephalitis in the Czech Republic, 2018-2022
title_sort 1757. effectiveness of vaccination against tick-borne encephalitis in the czech republic, 2018-2022
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679031/
http://dx.doi.org/10.1093/ofid/ofad500.1588
work_keys_str_mv AT kyncljan 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT angulofrederick 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT orlikovahana 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT zhangpingping 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT vlckovaiva 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT malymarek 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT krivohlavkovadagmar 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT harperlisa 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT edwardsjuanita 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT bendercody 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT pilzandreas 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT erberwilhelm 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT madhavaharish 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022
AT moisijennifer 1757effectivenessofvaccinationagainsttickborneencephalitisintheczechrepublic20182022